Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Last trade$50.86
Day change+$1.15 (+2.32%)
Day range$46.35 – $51.14
Volume715,670
Market cap$4.77B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.77B
Price / earnings
—
Price / book
211.25×
Price / sales
7.33×
EV / sales
8.07×
EV / EBITDA
-65.06×
Profitability
Earnings per share
-$1.27
Return on assets
-14.32%
Return on equity
-538.02%
Dividend yield
0%
Liquidity and leverage
Debt / equity
26.72×
Current ratio
3×
Quick ratio
2.95×
Cash ratio
0.59×
Cash flow
Price / cash flow
27.02×
Price / free cash flow
74.72×
Free cash flow
$63.85M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TVTX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$224.56M
$169.58M
$127.2M
$129.69M
$164.86M
$114.45M
$81.73M
$74.79M
Cost of revenue
$2.87M
$2.17M
$1.95M
$2.55M
$1.59M
$1.52M
$4.68M
$2.55M
Gross profit
$221.7M
$167.41M
$125.25M
$127.14M
$163.27M
$112.93M
$77.05M
$72.23M
Selling, general and administrative
$98.41M
$96.11M
$80.25M
$101.69M
$71.05M
$62.58M
$60.41M
$69.5M
Research and development
$183.42M
$60.28M
$57.09M
$57.87M
$51.89M
$49.36M
$46.89M
$62.07M
Total operating expenses
$289.8M
$163.46M
$162.16M
$159.56M
$138.34M
$125.58M
$119.73M
$132.97M
Operating income
-$68.11M
$3.95M
-$36.92M
-$32.43M
$24.93M
-$12.65M
-$42.67M
-$60.74M
Interest expense
-$2.14M
-$2.13M
-$2.3M
-$2.3M
-$2.75M
-$2.85M
-$2.86M
-$2.82M
Income before taxes
-$66.93M
-$35M
-$36.72M
-$21.07M
$25.71M
-$12.74M
-$41.19M
-$60.34M
Income taxes
-$5.9M
-$204K
-$120K
$921K
$8K
$20K
$39K
-$72K
Net income
-$52.34M
-$34.8M
-$37.1M
$2.73M
$25.71M
-$12.76M
-$41.23M
-$60.26M
Net income attributable to common shareholders
-$52.34M
-$34.8M
-$37.1M
$2.73M
$25.71M
-$12.76M
-$41.23M
-$60.26M
EBITDA
-$62.91M
$8.19M
-$11.7M
-$14.29M
$40.72M
$1.37M
-$29.87M
-$47.24M
Basic earnings per share
-$0.55
-$0.37
-$0.40
$0.03
$0.29
-$0.14
-$0.47
-$0.72
Diluted earnings per share
-$0.55
-$0.37
-$0.40
$0.04
$0.28
-$0.14
-$0.47
-$0.72
Recent news
Company coverage with links to the original publishers.
Travere Therapeutics reported Q3 2026 revenue of $224.56 million, up 36.2% year-over-year and beating consensus estimates by 16.64%. However, the company posted an EPS of -$0.55, significantly missing the -$0.25 consensus estimate. FILSPARI product sales surged 120.2% to $200.19 million, but license and collaboration revenue declined 91.6%. The stock carries a Zacks Rank #5 (Strong Sell) rating and has underperformed the market by 10.6% over the past month.
Travere Therapeutics (TVTX) reported a quarterly loss of $0.55 per share, significantly missing the consensus estimate of $0.25 loss, representing a -120% earnings surprise. While revenues of $224.56 million exceeded expectations by 16.64%, the company received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revision trends. The stock is expected to underperform the market in the near term despite outperforming the S&P 500 by 31.9% year-to-date.
Cytokinetics is expected to beat Q3 2026 earnings estimates with a positive Earnings ESP of +0.44% and Zacks Rank #3 (Hold). The company is projected to report a quarterly loss of $1.50 per share with revenues of $42.01 million, up 2065.5% year-over-year. The stock has beaten consensus EPS estimates in 2 of the last 4 quarters.
AstraZeneca announced FDA approval of Ultomiris (ravulizumab) for reducing proteinuria in adults with primary IgAN at risk of disease progression. This marks the drug's fifth U.S. indication and makes it the first C5 complement inhibitor approved for this use. Ultomiris sales grew 14% to $2.58 billion in H1 2026, though the company faces competition from Calliditas, Novartis, and Travere in the IgAN market.
Kuehn Law is investigating whether officers and directors of Travere Therapeutics breached fiduciary duties to shareholders through potential self-dealing. Long-term shareholders may be entitled to damages and corporate governance reforms.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.